首页 > 市场调查报告书 > 製药

癌症妇科治疗

市场调查报告书

商品编码

1379036

脂质体阿霉素市场：2023-2028 年全球产业趋势、份额、规模、成长、机会与预测

Liposomal Doxorubicin Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日期: 2023年11月02日 | 出版商:

IMARC | 英文 143 Pages | 商品交期: 2-3个工作天内

价格

简介目录图表

抽象的

2022年，全球脂质体阿霉素市场规模达到12亿美元。展望未来， IMARC Group预计到2028年市场规模将达到17亿美元，2022-2028年复合年增长率（CAGR）为6.0%。

脂质体阿霉素是一种化疗药物，用于治疗各种自体免疫疾病以及肝癌、乳癌、子宫内膜癌、胃癌和肾癌。它的作用是阻止或减缓体内癌细胞的生长。该药物被包裹在聚乙二醇化脂质体的脂肪覆盖物中，并透过注射进行静脉注射。阿霉素药物阻断癌细胞分裂和生长所需的酶，脂质体确保药物在血液中停留更长时间并到达癌细胞以增强疗效。药物剂量会根据患者的体重、身高和整体健康状况而变化。与传统使用的药物相比，脂质体阿霉素具有较小的毒性、骨髓抑制、脱髮和噁心。

脂质体阿霉素市场趋势：

全球骨肉瘤、多发性骨髓瘤、卵巢癌和自体免疫缺陷症候群（爱滋病）相关的卡波西氏肉瘤等慢性疾病的盛行率不断上升，是推动市场成长的关键因素之一。这可以归因于大多数工作人群久坐的生活方式和忙碌的日程安排，这反过来又显着增加了这些疾病的发生率，并对脂质体阿霉素药物的需求产生了积极影响。此外，大众对癌症可用治疗替代方案的认识不断提高，也推动了市场的成长。各种进步，例如典型奈米药物的开发和改进的化疗药物，正在充当其他生长诱导因素。这些创新促进了药物在体内的特定位点递送和受控释放。其他因素，包括医疗保健基础设施（尤其是发展中经济体）的显着改善，以及肿瘤学领域的广泛研发（R＆D）活动，预计将推动市场成长。

本报告回答的关键问题：

迄今为止，全球脂质体阿霉素市场表现如何，未来几年将如何表现？
COVID-19 对全球脂质体阿霉素市场有何影响？
主要区域市场有哪些？
基于产品的市场区隔是什么？
基于应用程式的市场区隔是什么？
产业价值链的各个阶段是什么？
该行业的关键驱动因素和挑战是什么？
全球脂质体阿霉素市场的结构如何？谁是主要参与者？
产业竞争程度如何？

白血病
- 市场走向
- 市场预测
骨肉瘤
- 市场走向
- 市场预测
乳癌
- 市场走向
- 市场预测
子宫内膜癌
- 市场走向
- 市场预测
肾癌
- 市场走向
- 市场预测
多发骨髓瘤
- 市场走向
- 市场预测
卡波西氏肉瘤
- 市场走向
- 市场预测
其他的
- 市场走向
- 市场预测

第 8 章：按地区分類的市场区隔

北美洲
- 美国
  - 市场走向
  - 市场预测
- 加拿大
  - 市场走向
  - 市场预测
亚太
- 中国
  - 市场走向
  - 市场预测
- 日本
  - 市场走向
  - 市场预测
- 印度
  - 市场走向
  - 市场预测
- 韩国
  - 市场走向
  - 市场预测
- 澳洲
  - 市场走向
  - 市场预测
- 印尼
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
欧洲
- 德国
  - 市场走向
  - 市场预测
- 法国
  - 市场走向
  - 市场预测
- 英国
  - 市场走向
  - 市场预测
- 义大利
  - 市场走向
  - 市场预测
- 西班牙
  - 市场走向
  - 市场预测
- 俄罗斯
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
拉丁美洲
- 巴西
  - 市场走向
  - 市场预测
- 墨西哥
  - 市场走向
  - 市场预测
- 其他的
  - 市场走向
  - 市场预测
中东和非洲
- 市场走向
- 按国家/地区分類的市场细分
- 市场预测

第 9 章：SWOT 分析

概述
优势
弱点
机会
威胁

第 10 章：价值链分析

第 11 章：波特五力分析

概述
买家的议价能力
供应商的议价能力
竞争程度
新进入者的威胁
替代品的威胁

第 12 章：价格分析

第13章：竞争格局

市场结构
关键参与者
关键参与者简介
- Baxter International Inc.
- Cipla Inc.
- Johnson & Johnson
- Merck KGaA
- Pfizer Inc.
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Ltd
- TTY Biopharm Company Limited
- Zydus Cadila

简介目录图表

Product Code: SR112023A3921

Abstract

The global liposomal doxorubicin market size reached US$ 1.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 1.7 Billion by 2028, exhibiting a growth rate (CAGR) of 6.0% during 2022-2028.

Liposomal doxorubicin is a chemotherapy drug used for the treatment of various autoimmune disorders and cancer of the liver, breast, endometrial, gastric and kidney. It functions by stopping or slowing cancer cell growth in the body. The medication is wrapped in a fatty covering of pegylated liposome and is administered intravenously through an injection. The doxorubicin drug blocks the enzymes required by cancer cells to divide and grow and the liposomes ensure that the drug stays in the bloodstream longer and reaches the cancer cells for enhanced efficacy. The dosage of the medication varies on the weight, height and general health of the patient. In comparison to the traditionally used drugs, liposome doxorubicin exhibits lesser toxicity, myelosuppression, alopecia and nausea.

Liposomal Doxorubicin Market Trends:

The increasing prevalence of chronic medical ailments, such as bone sarcoma, multiple myeloma, ovarian cancer and Autoimmune Deficiency Syndrome (AIDS)-related Kaposi sarcoma, across the globe is one of the key factors driving the market growth. This can be attributed to the sedentary lifestyles and hectic schedules of a majority of the working population, which, in turn, is significantly increasing the occurrence of these disorders and positively impacting the demand for liposomal doxorubicin drugs. Moreover, rising awareness among the masses regarding the available treatment alternatives for cancer is providing a thrust to the growth of the market. Various advancements, such as the development of paradigmatic nanodrugs and improved chemotherapeutic agents, are acting as other growth-inducing factors. These innovations facilitate site-specific delivery and controlled release of the drug in the body. Other factors, including significant improvements in the healthcare infrastructure, especially of the developing economies, along with extensive research and development (R&D) activities in the field of oncology, are anticipated to drive the market toward growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global liposomal doxorubicin market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on product and application.

Breakup by Product:

Doxil/Caelyx

Lipodox

Myocet

Others

Breakup by Application:

Leukemia

Bone Sarcoma

Breast Cancer

Endometrial Cancer

Kidney Cancer

Multiple Myeloma

Kaposi Sarcoma

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Baxter International Inc., Cipla Inc., Johnson & Johnson, Merck KGaA, Pfizer Inc., Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, TTY Biopharm Company Limited and Zydus Cadila.

Key Questions Answered in This Report:

How has the global liposomal doxorubicin market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global liposomal doxorubicin market?
What are the key regional markets?
What is the breakup of the market based on the product?
What is the breakup of the market based on the application?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global liposomal doxorubicin market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Liposomal Doxorubicin Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Product

6.1 Doxil/Caelyx
- 6.1.1 Market Trends
- 6.1.2 Market Forecast
6.2 Lipodox
- 6.2.1 Market Trends
- 6.2.2 Market Forecast
6.3 Myocet
- 6.3.1 Market Trends
- 6.3.2 Market Forecast
6.4 Others
- 6.4.1 Market Trends
- 6.4.2 Market Forecast

7 Market Breakup by Application

7.1 Leukemia
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Bone Sarcoma
- 7.2.1 Market Trends
- 7.2.2 Market Forecast
7.3 Breast Cancer
- 7.3.1 Market Trends
- 7.3.2 Market Forecast
7.4 Endometrial Cancer
- 7.4.1 Market Trends
- 7.4.2 Market Forecast
7.5 Kidney Cancer
- 7.5.1 Market Trends
- 7.5.2 Market Forecast
7.6 Multiple Myeloma
- 7.6.1 Market Trends
- 7.6.2 Market Forecast
7.7 Kaposi Sarcoma
- 7.7.1 Market Trends
- 7.7.2 Market Forecast
7.8 Others
- 7.8.1 Market Trends
- 7.8.2 Market Forecast

8 Market Breakup by Region

8.1 North America
- 8.1.1 United States
  - 8.1.1.1 Market Trends
  - 8.1.1.2 Market Forecast
- 8.1.2 Canada
  - 8.1.2.1 Market Trends
  - 8.1.2.2 Market Forecast
8.2 Asia-Pacific
- 8.2.1 China
  - 8.2.1.1 Market Trends
  - 8.2.1.2 Market Forecast
- 8.2.2 Japan
  - 8.2.2.1 Market Trends
  - 8.2.2.2 Market Forecast
- 8.2.3 India
  - 8.2.3.1 Market Trends
  - 8.2.3.2 Market Forecast
- 8.2.4 South Korea
  - 8.2.4.1 Market Trends
  - 8.2.4.2 Market Forecast
- 8.2.5 Australia
  - 8.2.5.1 Market Trends
  - 8.2.5.2 Market Forecast
- 8.2.6 Indonesia
  - 8.2.6.1 Market Trends
  - 8.2.6.2 Market Forecast
- 8.2.7 Others
  - 8.2.7.1 Market Trends
  - 8.2.7.2 Market Forecast
8.3 Europe
- 8.3.1 Germany
  - 8.3.1.1 Market Trends
  - 8.3.1.2 Market Forecast
- 8.3.2 France
  - 8.3.2.1 Market Trends
  - 8.3.2.2 Market Forecast
- 8.3.3 United Kingdom
  - 8.3.3.1 Market Trends
  - 8.3.3.2 Market Forecast
- 8.3.4 Italy
  - 8.3.4.1 Market Trends
  - 8.3.4.2 Market Forecast
- 8.3.5 Spain
  - 8.3.5.1 Market Trends
  - 8.3.5.2 Market Forecast
- 8.3.6 Russia
  - 8.3.6.1 Market Trends
  - 8.3.6.2 Market Forecast
- 8.3.7 Others
  - 8.3.7.1 Market Trends
  - 8.3.7.2 Market Forecast
8.4 Latin America
- 8.4.1 Brazil
  - 8.4.1.1 Market Trends
  - 8.4.1.2 Market Forecast
- 8.4.2 Mexico
  - 8.4.2.1 Market Trends
  - 8.4.2.2 Market Forecast
- 8.4.3 Others
  - 8.4.3.1 Market Trends
  - 8.4.3.2 Market Forecast
8.5 Middle East and Africa
- 8.5.1 Market Trends
- 8.5.2 Market Breakup by Country
- 8.5.3 Market Forecast

9 SWOT Analysis

9.1 Overview
9.2 Strengths
9.3 Weaknesses
9.4 Opportunities
9.5 Threats

10 Value Chain Analysis

11 Porters Five Forces Analysis

11.1 Overview
11.2 Bargaining Power of Buyers
11.3 Bargaining Power of Suppliers
11.4 Degree of Competition
11.5 Threat of New Entrants
11.6 Threat of Substitutes

12 Price Analysis

13 Competitive Landscape

13.1 Market Structure
13.2 Key Players
13.3 Profiles of Key Players
- 13.3.1 Baxter International Inc.
  - 13.3.1.1 Company Overview
  - 13.3.1.2 Product Portfolio
  - 13.3.1.3 Financials
  - 13.3.1.4 SWOT Analysis
- 13.3.2 Cipla Inc.
  - 13.3.2.1 Company Overview
  - 13.3.2.2 Product Portfolio
  - 13.3.2.3 Financials
  - 13.3.2.4 SWOT Analysis
- 13.3.3 Johnson & Johnson
  - 13.3.3.1 Company Overview
  - 13.3.3.2 Product Portfolio
  - 13.3.3.3 Financials
  - 13.3.3.4 SWOT Analysis
- 13.3.4 Merck KGaA
  - 13.3.4.1 Company Overview
  - 13.3.4.2 Product Portfolio
  - 13.3.4.3 Financials
  - 13.3.4.4 SWOT Analysis
- 13.3.5 Pfizer Inc.
  - 13.3.5.1 Company Overview
  - 13.3.5.2 Product Portfolio
  - 13.3.5.3 Financials
  - 13.3.5.4 SWOT Analysis
- 13.3.6 Sun Pharmaceutical Industries Ltd
  - 13.3.6.1 Company Overview
  - 13.3.6.2 Product Portfolio
  - 13.3.6.3 Financials
  - 13.3.6.4 SWOT Analysis
- 13.3.7 Teva Pharmaceutical Industries Ltd
  - 13.3.7.1 Company Overview
  - 13.3.7.2 Product Portfolio
  - 13.3.7.3 Financials
  - 13.3.7.4 SWOT Analysis
- 13.3.8 TTY Biopharm Company Limited
  - 13.3.8.1 Company Overview
  - 13.3.8.2 Product Portfolio
  - 13.3.8.3 Financials
- 13.3.9 Zydus Cadila
  - 13.3.9.1 Company Overview
  - 13.3.9.2 Product Portfolio

简介目录图表

List of Figures

Figure 1: Global: Liposomal Doxorubicin Market: Major Drivers and Challenges
Figure 2: Global: Liposomal Doxorubicin Market: Sales Value (in Billion US$), 2017-2022
Figure 3: Global: Liposomal Doxorubicin Market Forecast: Sales Value (in Billion US$), 2023-2028
Figure 4: Global: Liposomal Doxorubicin Market: Breakup by Product (in %), 2022
Figure 5: Global: Liposomal Doxorubicin Market: Breakup by Application (in %), 2022
Figure 6: Global: Liposomal Doxorubicin Market: Breakup by Region (in %), 2022
Figure 7: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market: Sales Value (in Million US$), 2017 & 2022
Figure 8: Global: Liposomal Doxorubicin (Doxil/Caelyx) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 9: Global: Liposomal Doxorubicin (Lipodox) Market: Sales Value (in Million US$), 2017 & 2022
Figure 10: Global: Liposomal Doxorubicin (Lipodox) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 11: Global: Liposomal Doxorubicin (Myocet) Market: Sales Value (in Million US$), 2017 & 2022
Figure 12: Global: Liposomal Doxorubicin (Myocet) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 13: Global: Liposomal Doxorubicin (Other Products) Market: Sales Value (in Million US$), 2017 & 2022
Figure 14: Global: Liposomal Doxorubicin (Other Products) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 15: Global: Liposomal Doxorubicin (Leukemia) Market: Sales Value (in Million US$), 2017 & 2022
Figure 16: Global: Liposomal Doxorubicin (Leukemia) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 17: Global: Liposomal Doxorubicin (Bone Sarcoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 18: Global: Liposomal Doxorubicin (Bone Sarcoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 19: Global: Liposomal Doxorubicin (Breast Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 20: Global: Liposomal Doxorubicin (Breast Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 21: Global: Liposomal Doxorubicin (Endometrial Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 22: Global: Liposomal Doxorubicin (Endometrial Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 23: Global: Liposomal Doxorubicin (Kidney Cancer) Market: Sales Value (in Million US$), 2017 & 2022
Figure 24: Global: Liposomal Doxorubicin (Kidney Cancer) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 25: Global: Liposomal Doxorubicin (Multiple Myeloma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 26: Global: Liposomal Doxorubicin (Multiple Myeloma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 27: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market: Sales Value (in Million US$), 2017 & 2022
Figure 28: Global: Liposomal Doxorubicin (Kaposi Sarcoma) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 29: Global: Liposomal Doxorubicin (Other Applications) Market: Sales Value (in Million US$), 2017 & 2022
Figure 30: Global: Liposomal Doxorubicin (Other Applications) Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 31: North America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 32: North America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 33: United States: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 34: United States: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 35: Canada: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 36: Canada: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 37: Asia-Pacific: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 38: Asia-Pacific: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 39: China: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 40: China: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 41: Japan: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 42: Japan: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 43: India: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 44: India: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 45: South Korea: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 46: South Korea: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 47: Australia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 48: Australia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 49: Indonesia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 50: Indonesia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 51: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 52: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 53: Europe: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 54: Europe: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 55: Germany: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 56: Germany: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 57: France: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 58: France: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 59: United Kingdom: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 60: United Kingdom: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 61: Italy: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 62: Italy: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 63: Spain: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 64: Spain: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 65: Russia: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 66: Russia: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 67: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 68: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 69: Latin America: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 70: Latin America: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 71: Brazil: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 72: Brazil: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 73: Mexico: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 74: Mexico: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 75: Others: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 76: Others: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 77: Middle East and Africa: Liposomal Doxorubicin Market: Sales Value (in Million US$), 2017 & 2022
Figure 78: Middle East and Africa: Liposomal Doxorubicin Market: Breakup by Country (in %), 2022
Figure 79: Middle East and Africa: Liposomal Doxorubicin Market Forecast: Sales Value (in Million US$), 2023-2028
Figure 80: Global: Liposomal Doxorubicin Industry: SWOT Analysis
Figure 81: Global: Liposomal Doxorubicin Industry: Value Chain Analysis
Figure 82: Global: Liposomal Doxorubicin Industry: Porter's Five Forces Analysis

List of Tables

Table 1: Global: Liposomal Doxorubicin Market: Key Industry Highlights, 2022 and 2028
Table 2: Global: Liposomal Doxorubicin Market Forecast: Breakup by Product (in Million US$), 2023-2028
Table 3: Global: Liposomal Doxorubicin Market Forecast: Breakup by Application (in Million US$), 2023-2028
Table 4: Global: Liposomal Doxorubicin Market Forecast: Breakup by Region (in Million US$), 2023-2028
Table 5: Global: Liposomal Doxorubicin Market: Competitive Structure
Table 6: Global: Liposomal Doxorubicin Market: Key Players

02-2729-4219

+886-2-2729-4219